GlaxoSmithKline Signs US$3 B Synthetic Lethality Alliance with IDEAYA Biosciences

By Michelle Liu

Pharma Deals Review: Vol 2020 Issue 6 (Table of Contents)

Published: 30 Jun-2020

DOI: 10.3833/pdr.v2020.i6.2546     ISSN: 1756-7874

Section: Research & Development



Highlighting its continued focus in oncology, GlaxoSmithKline (GSK) has agreed to partner with IDEAYA Biosciences for its synthetic lethality programmes targeting MAT2A, Pol Theta, and Werner Helicase...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: © IQVIA 2018

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details